Last update 13 Jul 2026

IMB-071703

Overview

Basic Info

Drug Type
Fab fragment, Bispecific antibody
Synonyms
IMB 071703, IMB071703
Target
4-1BB x PDL1
Action
agonists, inhibitors
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmNeoplasms
Inactive Indication-
Originator Organization
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., Ltd
Active Organization
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., Ltd
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with IMB-071703
CTR20254521
/ RecruitingPhase 1
IMB071703 注射液在复发或转移的晚期实体瘤患者中的安全性、耐受性、药代动力学特征和初步疗效的I期临床研究
[Translation] A Phase I clinical study of the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of IMB071703 injection in patients with recurrent or metastatic advanced solid tumors.
NCT06292858
/ Unknown statusPhase 1
A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Patients With Recurrent or Metastatic, Advanced Solid Tumors
100 Clinical Results associated with IMB-071703
Login to view more data
100 Translational Medicine associated with IMB-071703
Login to view more data
100 Patents (Medical) associated with IMB-071703
Login to view more data
100 Deals associated with IMB-071703
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., Ltd
24 Feb 2023
NeoplasmsIND Approval
United States
Beijng Immunoah Pharma Tech Co., LtdBeijng Immunoah Pharma Tech Co., Ltd
22 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free